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CancerChronic inﬂammation in tumor microenvironment plays an important role at different stages of tumor develop-
ment. The speciﬁcmechanisms of the association and its role in providing a survival advantage to the tumor cells
are not well understood. Mitochondria are emerging as a central platform for the assembly of signaling com-
plexes regulating inﬂammatory pathways, including the activation of type-I IFN and NF-κB. These complexes
in turn may affect metabolic functions of mitochondria and promote tumorigenesis. NLRX1, a mitochondrial
NOD-like receptor protein, regulate inﬂammatory pathways, however its role in regulation of cross talk of cell
death and metabolism and its implication in tumorigenesis is not well understood. Here we demonstrate that
NLRX1 sensitizes cells to TNF-α induced cell death by activating Caspase-8. In the presence of TNF-α, NLRX1
and active subunits of Caspase-8 are preferentially localized to mitochondria and regulate the mitochondrial
ROS generation. NLRX1 regulates mitochondrial Complex I and Complex III activities to maintain ATP levels in
the presence of TNF-α. The expression of NLRX1 compromises clonogenicity, anchorage-independent growth,
migration of cancer cells in vitro and suppresses tumorigenicity in vivo in nude mice. We conclude that NLRX1
acts as a potential tumor suppressor by regulating the TNF-α induced cell death and metabolism.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Clinical and experimental studies suggest that inﬂammation is in-
tricately linked with tumorigenesis. In colorectal, hepatic, breast and
several other cancer types, an inﬂammatory condition may precede
the development of malignancy [1–3]. For example, inﬂammatory
bowel disease (IBD) is associated with colon cancer and an infection
by Helicobacter pylori progressively leads to gastric carcinoma [3,4].
However, despite the numerous examples of the apparent associa-
tion of chronic inﬂammatory conditions with higher incidences of
cancer, the molecular mechanisms linking these pathologies are
still not well understood.
Inﬂammation, irrespective of its origin, promotes cell survival,
proliferation of malignant cells and conditions the tumor microenvi-
ronment for further metastasis. Emerging clinical reports suggestLaboratory, Engelhardt Institute
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stry, Faculty of Science, TheM.S.
65 2795594.
kov), singhraj1975@gmail.comthat the levels of speciﬁc cytokines are altered in patients with different
cancer types including breast, gastric, colorectal and hepatocellular car-
cinomas [5]. Increased levels of pro-inﬂammatory cytokines such as
tumor necrosis factor alpha (TNF-α), macrophage migration inhibitory
factor (MIF), transforming growth factor beta (TGF-β), interleukins-6,
-8, -10 and -18 (IL-6, IL-8, IL-10 and IL-18) were reported in patients
with advanced-stage pancreatic, colorectal and breast cancers [6–15].
Serum levels of TNF-αwere elevated in eight independent types of can-
cer including breast, colorectal and gastric carcinomas [5,9,13]. In tumor
microenvironment, TNF-α secreted by tumor cells or by inﬂammatory
cells, promotes tumor cell survival through the stimulation of NF-κB
pathway [16]. The activation of NF-κB up-regulates the expression of
genes stimulating cell cycle progression and promotes epithelial–mes-
enchymal transition [17]. The binding of TNF-α to Type I TNF receptor
(TNFR1) results in a pro-survival stimulation of NF-κB, through the
formation of proximal plasma membrane bound complex I consisting
of TNF receptor-associated protein with death domain (TRADD),
receptor-interacting protein 1 (RIP1) and TNF receptor-associated fac-
tor 2 (TRAF2). During the TNF-α induced apoptosis, the complex-I dis-
sociates from TNFR1 and recruits the Fas-associated death domain
(FADD) and Caspase-8, forming cytosolic complex-II, where Caspase-8
is activated, which further initiates the downstreamproteolytic cascade
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cate to different subcellular sites including mitochondria in response
to different stimuli [20–22]. TRADD, TRAF2 and RIP1 subunits of
complex-II together with Pro-caspase-8 have been reported to translo-
cate to mitochondria during the TNF-α induced apoptosis [23]. The
functional relevance of Caspase-8 and other subunits of complex-II
translocation to mitochondria is not clear.
Stimulation of the cells with TNF-α induces reactive oxygen spe-
cies (ROS) generation however the regulatory mechanisms in differ-
ent pathological conditions are still not clear. The mitochondrial
Complex I and Complex III are the major sites of ROS generation
[24]. Impaired Complex I and Complex III activities alter mitochon-
drial integrity by decreasing membrane potential, ATP synthesis
and oxygen consumption [25]. The alteration of mitochondrial func-
tions in response to TNF-α shifts the cancer cell metabolism toward
glycolysis [26] however the mechanisms are not well understood.
Upregulated glycolysis is a characteristic metabolic hallmark of can-
cer cells that is required to meet the bioenergetic demands. Thus,
TNF-α signaling may confer a selective advantage to cancer cells
for survival and proliferation through constitutive activation of NF-
κB and reprogramming of metabolism. However, molecular mecha-
nisms for the TNF-α-mediated regulation of mitochondrial bioener-
getic function remains elusive.
Mitochondria are emerging as a critical signaling platform for the as-
sembly of signallosomes regulating the inﬂammatory pathways [27].
Mitochondrial antiviral signaling protein (MAVS) localizes on the
outer membrane of mitochondria and serves as an adaptor protein for
RIG1, recognizing dsRNA during viral infections. MAVS is essential for
the type-I IFN and NF-κB activation during viral infections [28]. Recent
studies have suggested that COX5B, a subunit of Cytochrome c Oxidase
(CcO) complex negatively regulates antiviral innate immunity by
inhibiting MAVS signallosomes at the mitochondria [29]. Similarly, me-
diator of IRF3 activation (MITA) is a mitochondria-associated ER mem-
brane (MAM) protein located in the area of close juxtaposition between
mitochondria and ER. MITA is a crucial regulator of IFN and NF-κB
signaling during infection by DNA viruses [30]. The study from our
lab suggests that MITA is also an important regulator of inﬂamma-
tion acting as a potential tumor suppressor in breast cancer [31].
Similarly, a highly conserved NOD-like receptor with a mitochondria
localization signal, the nucleotide-binding domain (NBD) and
leucine-rich repeat (LRR)-containing family member X1 (NLRX1)
[32] is an important component of TLRmediated inﬂammatory path-
ways [33]. The role of the NLRX1 in regulating the cross talk of in-
ﬂammation and mitochondrial function and its involvement in
carcinogenesis is not well understood.
In the presentwork, we identify NLRX1 as a crucial regulator of TNF-
α induced cell death and reveal its potential role as a tumor suppressor.
We report here that NLRX1 sensitizes cells to the TNF-α induced apo-
ptosis by potentiating Caspase-8 at the level of complex-II. NLRX1 con-
tributes to the TNF-α induced generation of ROS by regulating the
activities of mitochondrial respiratory Complex I and Complex III.
NLRX1 negatively regulates clonogenic survival of tumor cells in vitro
and tumor growth in vivo by modulating oxidative phosphorylation
and metabolism.
2. Materials and methods
2.1. Cell culture and reagents
HEK293, HeLa, and MCF-7 cells were cultured in Dulbecco's mod-
iﬁed Eagle's media (DMEM, Life Technologies, Carlsbad, CA, USA).
T47D and MDA-MB-231 cells were cultured in RPMI 1640 (Life Tech-
nologies, USA) and Leibovitz's L-15 media (HI-MEDIA, India) respec-
tively. Media were supplemented with 10% (v/v) heat-inactivated
fetal bovine serum (Life Technologies), 1% penicillin, streptomycin
and neomycin (PSN) antibiotic mixture (Life Technologies). Fulllength NLRX1 (isoform 1) cloned into pcDNA3.1 vector was provided
by Dr. S E Girardin (University of Toronto, Ontario, Canada). Full length
TRIM13 and HA-TRAF2 were kind gifts from Dr. Olle Sangfelt (Depart-
ment of Oncology/Pathology, Cancer Centrum Karolinska, Stockholm,
Sweden) and Dr. S M Srinivasula (IISER, Thiruvananthapuram, Kerala,
India), respectively. The primary antibodies used were NLRX1, β-actin
and c-MYC (Abcam, Cambridge, UK), PARP, Caspase-8 (Cell Signaling
Technology, Inc., USA) and anti-HA peroxidase (Roche Applied Science,
IN, USA). HRP-conjugated anti-mouse and anti-rabbit antibodies (Ther-
mo Scientiﬁc, Inc., IL, USA) were used. TNF-α (Tumor Necrosis Factor-
alpha) and Mito-TEMPO were procured from Enzo Life Sciences, Inc.
USA. Cyclohexamide, antimycin, rotenone, H2O2, oligomycin and N-
Acetyl Cysteine (NAC) were purchased from Sigma-Aldrich, USA. z-
VAD-fmk (N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) ﬂuoromethyl
ketone) (BioVision, Inc., CA, USA), IETD-fmk (Ile-Glu(OMe)-Thr-
Asp(OMe)-ﬂuoromethyl ketone) (Clontech Laboratories, Inc., USA)
were used. CM-H2DCFDA and MitoSOX™ Red were purchased from
Molecular Probes Inc., USA.
2.2. Cell death and proliferation assay
Cell death and proliferationwas quantiﬁed by Trypan blue exclusion
assay and MTT assay respectively as previously described [31].
2.3. Generation of stable cell lines
MT-RFP stable cell line in MCF-7 was generated as previously de-
scribed to studymitochondrial localization of NLRX1 [34]. Similarly, sta-
ble knockdown of NLRX1 were generated in HEK293 and HeLa cells.
Cells were transfectedwithNLRX1 shRNA and control shRNA and stable
cloneswere selected andmaintained in puromycin (3 μg/ml) containing
DMEM.
2.4. Immunoprecipitation and Western blotting
For immunoprecipitation, HEK293 cells were plated at a density
of 2 × 106 cells/90 mm2 dish and transfected with indicated con-
structs using a calcium phosphate transfection method. After 24 h
of transfection, the cells were treated with TNF-α/CHX for an indi-
cated time interval, thereafter the cells were washed with cold
DPBS (Life Technologies) and harvested. Cells were lysed in NP40
IP lysis buffer (100 mM NaCl, 50 mM Tris–HCl, 10% Glycerol, 0.1%
Nonidet P-40) containing complete protease inhibitor cocktail
(Roche Applied Science, IN, USA) and incubated on ice for 1 h and
centrifuged at 13,000 rpm for 15 min at 4 °C. Supernatant was col-
lected and incubated overnight with Anti-HA Afﬁnity Matrix on a
roller shaker at 4 °C. The beads were washed three times with
NP40 IP lysis buffer, resuspended in 5 × SDS-PAGE sample buffer, re-
solved on 12% SDS-PAGE and analyzed by Western blotting using
speciﬁc antibodies.
For Caspase-8 and Caspase-3 immunoblotting, HEK293 cells were
plated at a density of 5 × 105 cells/well in a 6-well plate and transfected
with indicated constructs using calcium phosphate transfection meth-
od. After 24 h of transfection, the cells were treated with indicated re-
agents for speciﬁc time. The cells were harvested in cold PBS and lysed
in RIPA lysis buffer (150 mM NaCl, 50 mM Tris–HCl, 1% Triton X-100,
and complete protease inhibitor cocktail (Roche, Germany), and ana-
lyzed by Western blotting as indicated above. Western blot quantiﬁca-
tion was performed by densitometry using Image J 1.45 software
(NIH, MD, USA).
2.5. Caspase-8 luciferase assay
Caspase-8 activation assay was performed using Caspase-Glo® 8
Assay Systems (Promega, USA) according to manufacturer instructions
as described previously [35].
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Mitochondrial localization of NLRX1 was monitored by confocal mi-
croscopy. Brieﬂy, MT-RFP-MCF-7 stable cell line were plated on cover
slip at the density of 1.5 × 105 cells/well in a 24-well plate followed by
transfectionwith indicated expression vector. After 24 h of transfection,
the cells were treatedwith TNF-α for four hours andﬁxedwith 4% para-
formaldehyde. The cells were monitored by Zeiss LSM 710 confocal mi-
croscope (Carl Zeiss, Inc., Germany). Images were captured, pseudo-
colored and analyzed by Zen Black software. Colocalization was quanti-
ﬁed by correlation using Image J 1.45 software (NIH, MD, USA).
2.7. Subcellular fractionation and Western blotting
Mitochondrial localization of NLRX1 and Caspase-8 were analyzed
by Western blotting using isolated mitochondria. HEK293 cells were
plated at the density of 2 × 106 cells/90 mm2 dish and transfected
with indicated constructs using calcium phosphate transfection meth-
od. Cells were treated with TNF-α/CHX for 8 h and washed with cold
PBS, harvested by centrifugation at 600 ×g for 10 min. Cell pellets
were resuspended in mitochondria isolation buffer (200 mMmannitol,
70 mM sucrose, 1 mM EGTA, 10mMHEPES; pH 7.4, 1× protease inhib-
itor cocktail (Sigma-Aldrich, USA) and incubated on ice for 5 min. The
cells were disrupted by passing through a 24G sterile syringe needle
and centrifuged at 600 ×g for 10 min to separate nuclei and cell debris.
The supernatant (cytosolic fraction) was collected and centrifuged
again at 10,000 ×g for 10 min. The pellet (mitochondrial fraction)
were washed twice with isolation buffer and lysed with mitochondria
lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA,
2 mM EGTA, 0.2% Triton X-100, 0.3% NP40 and 1× Protease Inhibitor
Cocktail. The mitochondrial and cytosolic protein concentrations were
assessed using Bradford protein estimation assay. Equal proteins were
loaded and resolved on 12% SDS-PAGE and analyzed by Western blot-
ting using indicated antibodies.
2.8. ROS measurements
Intracellular and mitochondrial ROS production was measured by
CM-H2DCFDA (10 μM) and MitoSOX Red (5 μM) staining respectively.
Brieﬂy, HEK293 and HeLa cells were plated in 24-well plates at the den-
sity of 1.5 × 105 cells/well. After overnight incubation, the cells were
transfected with NLRX1 and NLRX1 shRNA1 using calcium phosphate
transfection protocol. Twenty-four hours post transfection, the cells
were treated with indicated reagents for 4 h and stained with indicated
reagent and monitored under ﬂuorescence microscope (Olympus IX81
microscope; Olympus, Tokyo, Japan). Minimum of 5 images and 80–
100 cells were used for analysis.
Similarly, ROS levels were quantiﬁed by ﬂuorometry. Brieﬂy, MCF-7
and HEK293 cells were transfected with indicated constructs. The
cells were treated with indicated reagents for 4 h and stained with
CM-H2DCFDA (12.5 μM) in DPBS for intracellular ROS quantiﬁcation
and MitoSOX Red (2.5 μM) in DMEM for mitochondrial superoxide
quantiﬁcation. The cells were washed with DPBS and normalized
to1 × 106 cells/ml. Fluorescence intensity was quantiﬁed by ﬂuorom-
eter (Hitachi High-Technologies Corp., Japan) with excitation/emis-
sion at 495/520–540 nm and 510/570–600 nm, respectively.
2.9. Mitochondrial Complex I and Complex III assays
The activities of mitochondrial Complex I and Complex III was ana-
lyzed spectrophotometrically. Brieﬂy, HEK293 cells were seeded at the
density of 5 × 105 cells/well in the 6-well plate. After overnight incuba-
tion, the cells were transfected with indicated construct using calcium
phosphate transfection protocol and treated as indicated. The NLRX1
knockdown stable cell line and the NLRX1 expressing cells were har-
vested and washed with cold DPBS. The cells were subjected to 2–3freeze–thaw cycles in a freeze–thaw complete solution (0.25M sucrose,
20 mM Tris–HCl (pH 7.4), 40 mM KCl, 2 mM EDTA supplemented with
1 mg/ml fatty acid-free BSA, 0.01% Digitonin and 10% Percoll). The cells
were washed again with the freeze–thaw solution devoid of digitonin
and resuspended in Complex I assay buffer (35 mM potassium phos-
phate (pH 7.4), 1 mM EDTA. 2.5 mM NaN3,1 mg/ml BSA, 2 μg/ml
antimycin A, 5 mM NADH). The reaction was started by adding 80 μg
of cell lysate to 500 μl of assay buffer in 1 ml quartz cuvette. Complex I
activity was measured for 3 min by monitoring the decrease in absor-
bance at 340 nm after the addition of 2.5 mMacceptor decylubiquinone
indicating the oxidation of NADH.
Similarly, for Complex III activity, NLRX1 knockdown stable cells
were seeded at a density of 2.5 × 106 cells/90 mm2 dish. The cells
were harvested and washed with cold DPBS. All the subsequent
steps were performed at 4 °C. The cells were suspended in 0.5 ml of
20 mM hypotonic potassium phosphate buffer (pH 7.5) and lysed
using a 24G sterile syringe and subjected to freeze–thaw cycle. The
cell lysate (80 μg) was added to the 500 μl of Complex III assay buffer
(25 mM potassium phosphate (pH 7.5), 0.025% Tween-20, and
300 μM NaN3, 75 μM Cytochrome c) in cuvette and the baseline ob-
servance was monitored at 550 nm for 2 min. The reaction was
started by the addition of 100 μM decylubiquinol (freshly prepared
2.5 mM stock) monitoring the increase in absorbance at 550 nm for
2 min.
2.10. ATP measurements
The levels of ATP were measured in NLRX1 expressing and NLRX1
KD cells under different conditions by an ATP dependent luciferase
assay using ATP determination kit (Molecular Probes/Life Technologies,
ON, Canada).
2.11. Soft agar assay, colony formation assay and scratch assay
Anchorage-independent potential was assessed by soft agar assay,
clonogenic activity and migration ability of cancer cells were deter-
mined as described previously [31,36].
2.12. Animal experiments
Animal studies were performed according to the rules and protocols
approved by the Bioethical committee of the Engelhardt Institute of
Molecular Biology, Moscow, Russia. A total of 48 nude mice
(5 week old Balb/c nu/nu) were used in the current expeiment.
RKO colon carcinoma cells carrying empty lentiviral vector pLSLP,
NLRX1 shRNA1 (Sigma TRCN0000129459) and over expressing
NLRX1 (lentiviral construct pLCMV-NLRX1-puro) were used. Cells
were trypsinized, washed three times in ice-cold PBS and inoculated
subcutaneously in four locations (left and right hind and shoulders) at
a density of 1 × 106 cells in 0.1 ml per inoculum. Fifteen micrograms
of puriﬁed human recombinant TNF-α (gift of Dr. Alexey Sazykin,
Moscow State University) was inoculated intraperitoneally 24 h later,
and control mice were inoculated with PBS. The mice were inspected
every two days and tumor size was measured. Tumor volume was cal-
culated according to the following formula: ellipsoid volume: 1/
6 ∗ pi ∗ a ∗ b ∗ c, where a, b, and c are linear sizes of the tumor in three
dimensions.
Expression levels of NLRX1 transcripts in the cell lines were moni-
tored by real time PCR with EVA-green dye.
The following primers were used:
NLRX1-For: AACGGTGCTGGTGACACA;
NLRX1-Rev: GCTCAGCTCATTGAAGTAGA.
The level of NLRX1 inhibition was 85% in RKO cells. Levels of NLRX1
transcripts in the hyperexpressor cell lines were 8-fold compared to
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2.13. Statistical analysis
Data are expressed asmean± SEM of at least two or three indepen-
dent experiments. Unpaired two-tailed Student's t tests were per-
formed unless otherwise noted and *P b 0.05, **P b 0.01 and
***P b 0.001 were considered to denote signiﬁcance. GraphPad Prism®
was used to perform all the statistical analyses.
3. Results
3.1. NLRX1 sensitizes TNF-α induced cell death
To study the role of NLRX1 in regulation of cell death and survival
in response to different physiological stress, we transfected HEK293
cells with NLRX1, exposed the cells to different stimuli and monitored
cell death by trypan blue exclusion assay (Fig. 1A). The expression ofFig. 1. NLRX1 regulates TNF-α induced cell death. (A) HEK293 cells were transfected with NLR
TNF-α/CHX (10 ng/25 μM). The cell death wasmonitored by Trypan blue exclusion assay. (B) H
targeting NLRX1, namely NLRX1 shRNA 1, 2 and 3. Cell lysates were analyzed for NLRX1 expres
shRNA targeting NLRX1. Cells were subjected to TNF-α/CHX treatment for 24 h and analyzed ce
were treated with TNF-α/CHX for 6 h. Cell lysates were subjected toWestern blotting with PAR
performed using densitometry and ratios of cleaved to uncleaved PARP are indicated (results are
values (n = 3). Asterisk (*) indicates that p value b 0.05, for SEM.NLRX1 had no signiﬁcant effect on cell survival in the untreated condi-
tions. The expression of NLRX1 showed no effect on cell death in re-
sponse to oxidative stress induced by Rotenone and H2O2. The co-
treatment of NLRX1-expressing cells with TNF-α and the translation in-
hibitor cyclohexamide (CHX) showed signiﬁcantly increased cell death
(Fig. 1A). Similarly, transfection of HeLa cells with NLRX1 signiﬁcantly
increased the number of trypan blue positive cells following the TNF-
α/CHX treatment (Fig. S1A). These results suggest that NLRX1 speciﬁ-
cally sensitizes the cells to TNF-α induced death. This conclusion was
further conﬁrmed by downregulating NLRX1 using speciﬁc shRNA in
HEK293 cells. Three different shRNAs were checked for the efﬁcient
knockdown of NLRX1. The shRNA1 of NLRX1 showedmaximum down-
regulation hence it was further used in the study (Fig. 1B). The con-
structs expressing NLRX1-speciﬁc shRNAs were transfected to HEK293
cells and cell death was monitored by trypan blue exclusion staining.
Knockdown of NLRX1 by all of the shRNAs increased the cell survival
following TNF-α/CHX treatment, although signiﬁcant increase was
achieved with shRNA1 (Fig. 1C). Similarly, the transfection of NLRX1
shRNA1 inHEK293 showedmaximumcell survival (Fig. S1B). To furtherX1 and vector control followed by treatment with Rotenone (50 μM), H2O2 (100 μM) and
EK293 cells were transfected with control shRNA, NLRX1-Flag and three different shRNAs
sion byWestern blotting. (C) HEK293 cells were transfectedwith control shRNA and three
ll death by Trypan blue staining. (D) NLRX1 shRNA and control shRNA stable HEK293 cells
P speciﬁc antibody. (E) Quantiﬁcation of PARP cleavage detected byWestern blotting was
representative of two independent experiments). Data in (A) and (C) depictmean± SEM
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blottingwas performed after NLRX1 knockdown. PARP is cleaved by ex-
ecutioner caspases during TNF-α induced apoptosis [37]. NLRX1
knockdown HEK293 cells were treated with TNF-α/CHX for 6 h and
PARP cleavage was monitored. Western blotting showed 110 kDa and
89 kDa band corresponding to native and cleaved form of PARP in con-
trol shRNA transfected cells. The knockdown of NLRX1 showed de-
creased levels of 89 kDa bands corresponding to cleaved subunit of
PARP as compared to the control (Fig. 1D, E). To rule out the possibility
of a cell line-speciﬁc phenomenon, the expression of NLRX1 in MCF-7
cells also showed increased levels of cleaved PARP subunit as compared
to vector transfected cells (Fig. S1C). Collectively, the results indicate
that NLRX1 is an important regulator of TNF-α induced cell death. The
similar study from Soares et al. [38] also reported a key role of NLRX1
in cell death and cancer susceptibility during the preparation of the
manuscript. Several ﬁndings from our study is in consonance with this
study, however, the two studies differ in respect to the response to
TNF-α/CHX treatment. It is highly probable that transformed cell lines
with a variable expression level of NLRX1 may differ in sensitivity to
TNF-α/CHX. The cell death data reported in the current study showed
different levels of cell death in HEK293, MCF-7 breast and HeLa which
had a different expression level of NLRX1.3.2. Caspase activation is essential for the NLRX1 mediated sensitization of
TNF-α induced cell death
The cleavage of PARP suggests the activation of caspases in the pres-
ence of NLRX1. The activation of caspases plays amajor role in TNF-α in-
duced cell death [18] hence we planned to conﬁrm the role of caspases
in the NLRX1mediated sensitization to TNF-α induced cell death. First-
ly, we analyzed Caspase-8 and Caspase-3 activations at different time
points by Western blotting (Fig. 2A). High levels of 41 kDa and 18 kDa
bands corresponding to cleaved subunits p43 and p18 of Caspase-8
were detected as early as 4 h in the presence of TNF-α/CHX in NLRX1
transfected HEK293 cells, as compared to vector transfected cells
(Fig. 2A). Similarly, a 17 kDa band corresponding to the cleaved subunit
of Caspase-3 was detected 4 h after the TNF-α/CHX treatment (Fig. 2A).
Quantiﬁcation of Caspase-8 activity was also monitored at different
time points in HEK293 cells transfected with vector control and
NLRX1 in the presence of TNF-α/CHX. The enzymatic activity of
Caspase-8 was high at 4 h and remained elevated till 8 h in NLRX1
transfected cells as compared to vector control (Fig. 2B). Similarly, the
expression of NLRX1 in MCF-7 cells showed increased levels of cleaved
Caspase-8 subunits as compared to vector transfected cells in the pres-
ence of TNF-α/CHX. (Fig. S1C). Conversely, knockdown of NLRX1 in
HEK293 cells showed a signiﬁcant decrease in the levels of cleaved sub-
units of Caspase-8 (p43 and p18) as compared to control (Fig. 2C).
To conﬁrm the role of NLRX1 in TNF-α induced Caspase-8 activation
and cell death, Caspase-8 activity was monitored upon co-treatment of
the cells with the pan-caspase inhibitor, z-VAD-fmk and TNF-α/CHX at
the 4 h time point. A decrease in Caspase-8 enzymatic activity was ob-
served following inhibition of caspases in NLRX1 transfected cells
(Fig. 2D). This result was conﬁrmed by Western blotting showing re-
duced levels of cleaved Caspase-8 subunits in the presence of z-VAD-
fmk (Fig. 2E). Similarly, HEK293 cells were transfected with NLRX1,
treated with TNF-α or with TNF-α/CHX in the absence or presence of
the pan-caspase inhibitor z-VAD-fmk andmonitored cell death.We ob-
served no signiﬁcant difference in cell death between NLRX1-
transfected and vector-transfected cells, both in untreated conditions
and in the presence of TNF-α. Treatment with TNF-α/CHX sensitized
NLRX1 expressing cells to TNF-α induced cell death as observed earlier.
The co-treatment of the NLRX1 expressing cells with TNF-α/CHX and z-
VAD-fmk attenuated cell death (Fig. 2F). Interestingly, the co-treatment
of cellswith the Caspase-8 speciﬁc inhibitor z-IETD-fmk signiﬁcantly in-
creased cell survival as assessed by trypan blue staining. All the aboveevidences strongly suggest the role of NLRX1 in regulation of TNF-α-
mediated Caspase-8 activation.
3.3. NLRX1 associates with the TNF-α induced complex-II to promote
Caspase-8 activity
The binding of TNF-α to its cell surface receptor and formation of
complex-II initiates cell death program by recruiting Caspase-8 and
other adaptor proteins. The observed stimulation of Caspase-8 activity
by NLRX1 as early as 4 h after TNF-α/CHX treatment suggests that
NLRX1 may act at the level of complex-II formation. Recent studies im-
plicate an essential role of ubiquitin ligases in the assembly and activa-
tion of Caspase-8 [35,39,40]. RING family E3 ligase TRAF2 interacts with
Caspase-8 at complex-II and sets a threshold for Caspase-8 activation
[39]. Similarly, our recent observation has demonstrated the role of
the RING E3 ligase, TRIM13 in regulation of Caspase-8 activation down-
stream of complex-II [35]. We planned to test the association of NLRX1
with TNF-α induced signaling complexes and the role of the E3 ligases
in regulation of NLRX1 mediated activation of Caspase-8. HEK293 cells
were co-transfected NLRX1 with TRAF2 and TRIM13 and were treated
with TNF-α/CHX. In agreement with our earlier report [35], the expres-
sion of TRIM13 increased the levels of 41 kDa and 18 kDa bands corre-
sponding to processed Caspase-8 in the absence/presence of TNF-α/
CHX (Fig. 3A). However, the co-expressions of TRIM13 and NLRX1 de-
creased the activation of Caspase-8 in the presence of TNF-α/CHX. Sim-
ilarly, in agreement with earlier report the expression of TRAF2
attenuated the processing and activation of Caspase-8 to that of control
level. Co-expression of TRAF2 signiﬁcantly reversed the NLRX1-
mediated increase in levels of processed Caspase-8 in presence of
TNF-α. Taken together, the data supported our hypothesis that NLRX1
affects the activity of Caspase-8 at the level of complex-II formed after
TNF-α stimulation. To test whether NLRX1 may interact with compo-
nents of complex-II, we performed co-immunoprecipitation (IP) analy-
sis. We co-expressed NLRX1 along with HA-TRAF2 and Myc-RIP1 in
HEK293 cells, treated the cells with TNF-α/CHX for 5min and 8 h to an-
alyze Complexes I and -II, respectively. We immunoprecipitated TRAF2,
a subunit of both complexeswithHA-antibodies and analyzed the inter-
actions. ByWestern blotting we identiﬁed a 110 kDa band correspond-
ing to NLRX1, a 78 kDa band of RIP1 and Casaspe-8, after eight hours of
TNF-α/CHX treatment. There was no pull down of NLRX1, RIP1 and
Caspase-8, after ﬁve minutes of TNF-α/CHX treatment (Fig. 3B). The re-
sult indicates that NLRX1 associates with TNF-α induced signaling
complex-II to promote the activation of Caspase-8.
3.4. NLRX1 localizes tomitochondria and augments the TNF-α induced ROS
production
NLRX1 localizes tomitochondria, although its functional signiﬁcance
is still not well understood. Similarly, Caspase-8 is also known to be lo-
calized to mitochondria hence, we hypothesized that the crosstalk be-
tween NLRX1 and Caspase-8 may regulate mitochondrial function in
response to TNF-α. We analyzed the cellular localization of NLRX1 in
the absence/presence of TNF-α. We transfected MCF-7-MT-RFP stable
cell linewith NLRX1-GFP andmonitored the cellular localization of pro-
teins by confocal microscopy. We observed that a signiﬁcant fraction of
NLRX1 co-localizes with mitochondria (Fig. 4A, B) in the presence of
TNF-α. This observation was further conﬁrmed by subcellular fraction-
ation. The mitochondrial and cytoplasmic fractions from the TNF-α/
CHX treated NLRX1-HEK293 cells were analyzed by Western blotting.
The high level of pro-caspase-8 was detected (the 55 kDa band) in the
mitochondrial fraction of untreated cells. The increased levels 43 kDa
and 18 kDa corresponding to the cleaved subunits of Caspase-8 (p43
and p18) were higher in NLRX1 transfected mitochondrial fraction as
compared to vector control in the presence of TNF-α/CHX. NLRX1 was
speciﬁcally enriched in the mitochondrial fraction of both untreated
and treated cells (Fig. 4C). The quality of mitochondrial and cytosolic
Fig. 2.NLRX1 regulates Caspase-8 activity during TNF-α induced cell death. (A)HEK293 cellswere transfectedwith NLRX1 and treatedwith TNF-α/CHX for indicated time. The cell lysates
were analyzed by Western blotting using Caspase-8 and Caspase-3 speciﬁc antibodies. (B) HEK293 cells were transfected and treated as indicated in (A) and Caspase-8 activity was an-
alyzed at different time points by Caspase-8 Glo luciferase assay system (n= 2).(C) NLRX1 shRNA and control shRNA stable HEK293 cells were treated with TNF-α/CHX for 4 h and Cas-
pase-8 activationwas analyzed byWestern blotting. (D and E) HEK293 cells were transfectedwith NLRX1 and vector and treatedwith TNF-α/CHX or TNF-α/CHX and z-VAD-fmk (20 μM)
for indicated time. The Caspase-8 activation was analyzed by Caspase-8 Glo luciferase assay system (n= 2) (D) andWestern blotting (E). (F) HEK293 cells were transfected with NLRX1
and vector control followed by treatment with TNF-α/CHX, z-VAD-fmk (20 μM) and z-IETD-fmk (10 μM). After 24 h of treatment, cell deathwasmeasured by trypan blue exclusion assay
(n = 3). Asterisk (*) indicates that p value b 0.05, for SEM.
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tochondrial Complex I, and to RPS9, a component of 40S ribosomal sub-
unit. The NDUFS2 was found exclusively in the mitochondrial fraction
whereas RPS9 was detected only in the cytosol. Together, these results
demonstrate that NLRX1 localizes to mitochondria in the presence of
TNF-α/CHX.
Emerging evidences suggest that caspases may cleave subunits of
the ETC and regulate ROS during different stress conditions [41]. The
role of the crosstalk between NLRX1 and Caspase-8 in regulation of
ROS and activity of mitochondrial complexes of ETC is not well under-
stood. To test whether NLRX1 may regulate TNF-α induced ROS gener-
ation, the NLRX1 knockdown HeLa cells were treated with TNF-α/CHX
and stained with the oxidant-sensitive dye, CM-H2DCFDA. As expected,
the TNF-α/CHX treatment increased ROS levels in control cells. Interest-
ingly, the knockdown of NLRX1 substantially attenuated the TNF-α/CHX stimulated generation of ROS (Fig. 5A). To conﬁrm this, intracellu-
lar ROS formation in HEK293 cells was quantiﬁed in the presence of
TNF-α/CHX alone or in combination with N-Acetyl Cysteine (NAC), an
antioxidant. ROS generation was signiﬁcantly decreased in NLRX1
knockdown (KD) HEK293 cells while co-treatment with NAC further
suppressed ROS level in NLRX1 KD HEK293 cells in the presence of
TNF-α/CHX (Fig. 5B). Based on these results, we concluded that
NLRX1 localizes to mitochondria and participates in the TNF-α induced
ROS generation.
Mitochondria is one of the major sites of ROS under different stress
conditions. We hypothesized that a cross talk between NLRX1 and
Caspase-8 may regulate mitochondrial function, including the genera-
tion of ROS. To test this possibility,mitochondrial superoxide generation
in NLRX1 and vector transfectedMCF-7 cells was quantiﬁed in the pres-
ence of TNF-α/CHX alone or in combination with Mito-TEMPO, a
Fig. 3.NLRX1 interacts with complex-II during TNF-α induced cell death. (A) HEK293 cells
were cotransfected with NLRX1 in combination with TRAF2 and TRIM13. The cells were
treatedwith TNF-α/CHX for 4 h. Cell lysates were analyzed byWestern blotting with Cas-
pase-8 antibody. (B) HEK293 cells were transfected with NLRX1-Flag, HA-TRAF2, Myc-
RIP1 followed by co-treatment with TNF-α/CHX for 5 min and 8 h. Immunoprecipitation
with anti-HA antibodywas performed and interacting proteinswere analyzed byWestern
blotting with indicated antibodies.
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cantly induced mitochondrial ROS in the presence of TNF-α/CHX
while co-treatment with Mito-TEMPO suppressed superoxide forma-
tion as compared to vector control (Fig. 5C). Similarly, we treated
NLRX1 transfected HEK293 cells with TNF-α/CHX and mitochondrial
ROS level was analyzed by staining cells with MitoSOX Red and visual-
ized under ﬂuorescence microscope. NLRX1 expression alone stimulat-
ed mitochondrial superoxide formation in untreated condition which
further increased signiﬁcantly in the presence of TNF-α/CHX as com-
pared to vector control (Fig. S2A).
To determine the role of Caspase-8 in ampliﬁcation of TNF-α in-
duced ROS generation, HeLa cells expressing NLRX1 were pretreated
with z-IETD-fmk, then treated with TNF-α/CHX and the intracellular
ROS was assessed by CM-H2DCFDA staining. ROS levels were signiﬁ-
cantly increased in NLRX1 transfected cells as compared to vector
transfected cells in the presence of TNF-α/CHX. The inhibition of
Caspase-8 with z-IETD-fmk decreased the level of ROS in NLRX1
transfected cells treated with TNF-α/CHX (Fig. 5D). ROS quantiﬁcation
in MCF-7 cells transfected with NLRX1 and vector control yielded simi-
lar results both in the presence of TNF-α/CHX and co-treatment with z-
IETD-fmk (Fig. 5E). We also tested whether blocking ROS generation
may rescue TNF-α/CHX induced death of NLRX1 expressing MCF-7
and HEK293 cells. As observed earlier, expression of NLRX1 had no sig-
niﬁcant effect on cell survival in the untreated conditions and in the
presence of Rotenone and H2O2. Treatment with TNF-α/CHX sensitized
NLRX1 expressing cells to TNF-α induced cell death, in contrast, co-
treatment with NAC signiﬁcantly increased cell survival of NLRX1
transfected cells as compared to vector transfected cells (Fig. S2B).Similar results were obtained in HEK293 cells transfected with NLRX1
and treated with TNF-α/CHX along with Mito-TEMPO (Fig. S2C). All to-
gether, these data suggested that NLRX1 regulates Caspase-8 activity to
modulate mitochondrial ROS and cell death during TNF-α induced
apoptosis.
3.5. NLRX1 regulates mitochondrial respiratory Complex I and Complex III
to maintain ATP levels in the presence of TNF-α
As Complex I and Complex III of the mitochondrial electron trans-
port chain are the major sites for ROS generation [42], hence we tested
if NLRX1 expression may regulate their activity. The expression of
NLRX1 in HEK293 cells decreased Complex I activity in the presence of
TNF-α, but not after co-treatment with TNF-α and CHX. Interestingly,
inhibition of Caspase-8 by z-IETD-fmk signiﬁcantly increased
Complex-I activity in the presence of TNF-α/CHX (Fig. 6A). Similarly,
the treatment of cells with pan-caspase inhibitor z-VAD-fmk enhanced
Complex I activity to the same level in both NLRX1 expressing and con-
trol cells. Conversely, the activity of respiratory Complex I increased,
both in the absence/presence of TNF-α in shNLRX1 transfected cells
(Fig. 6B). Similarly, the knockdown of NLRX1 in HEK293 cells increased
Complex III activity, as compared to control cells, both in the absence
and presence of TNF-α (Fig. 6C).
The above experiments suggest that NLRX1 regulates the activity of
mitochondrial complexes which is the major source of ATP generation
in the cell. Therefore, we investigated whether the expression of
NLRX1 might regulate total cellular and mitochondrial ATP levels in
the presence of TNF-α. The expression of NLRX1 in HEK293 cells de-
creased total cellular steady-state ATP level in the presence of TNF-α
whereas the decrease was less evident when the cells were co-treated
with TNF-α and CHX (Fig. 6D). The ATP levels were measured after
16 h of treatment with TNF-α/CHX, hence, the activated caspases may
have cleaved the subunits of ETC complexes as observed earlier [23]
and the decrease may not be evident. Importantly, the inhibition of
Caspase-8 by z-IETD-fmk during TNF-α/CHX induced apoptosis signiﬁ-
cantly enhanced the ATP levels in NLRX1 expressing cells, while addi-
tion of z-VAD-fmk showed no signiﬁcant effect on the levels of ATP.
The inhibitionmay not be observed as z-VAD-fmk is not a potent inhib-
itor of the initiator caspases [43] further suggesting that activated
caspase-8 may directly act on complexes of ETC in the presence of
NLRX1. Total ATP levels in the NLRX1 KDHEK293 cells were signiﬁcant-
ly higher in both TNF-α and TNF-α/CHX treated cells (Fig. 6E). The mi-
tochondrial ATP levels in NLRX1 KD HEK293 cells increased both in the
absence/presence of TNF-α (Fig. S2D). Similar results were observed in
MCF-7 breast carcinoma cells where NLRX1 expression showed a signif-
icant decrease in total ATP level both in the absence/presence of TNF-α
(Fig. S2E). These results strongly suggest that NLRX1 regulates activity
of mitochondrial complexes and maintenance of intracellular levels of
ATP.
3.6. NLRX1 expression suppresses clonogenic ability, anchorage-independent
growth and migration of cancer cells in vitro
The NLRX1 mediated decrease in mitochondrial respiratory com-
plex activity suggests its important role in cancer cell metabolism.
Extracellular acidiﬁcation of tumor microenvironment is a common
feature of tumor tissue. The acidic pH is attributed to a switch from
mitochondrial respiration to aerobic glycolysis, which is a character-
istic hallmark of cancer cells [30]. Interestingly, we observed that
knockdown of NLRX1 in HeLa cells reversed the acidiﬁcation of the
culture medium (Fig. S2F), suggesting that NLRX1 may contribute
to the metabolic switch toward glycolysis in tumor cells.
As we observed above that NLRX1 canmodifymitochondrialmetab-
olism and promote aerobic glycolysis, it may have an implication in reg-
ulating the clonogenic and tumorigenic potentials of tumor cells. We
analyzed the NLRX1 expression in different cancer types available in
Fig. 4.NLRX1 translocates tomitochondria and regulates Caspase-8 activity at themitochondria in the presence of TNF-α. (A)MCF-7-MT-RFP stable cell linewas transfectedwith NLRX1-
GFP and GFP control. After 24 h of transfection, cells were treated with TNF-α, ﬁxed with 4% paraformaldehyde and visualized by confocal microscopy. Scale bar in the upper and lower
panel represents 10 μm and 5 μm, respectively. (B) Colocalization quantiﬁcation of confocal images by Pearson's correlation coefﬁcient (Rr) was performed using Image J 1.45 software
(NIH, MD, USA). (C) HEK293 cells were transfected with NLRX1 and control vector followed by treatment with TNF-α/CHX for 4 h. Cells were subjected to subcellular fractionation. Mi-
tochondrial and cytoplasmic fractions from untreated and treated cells were analyzed by Western blotting with indicated antibodies. Asterisk (*) indicates that p value b 0.05, for SEM.
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breast and cervical cancers (Gene Expression across Normal and Tumor
tissues (GENT), Fig. S3A, (http://medicalgenome.kribb.re.kr/GENT)).
Similarly, protein expression levels of NLRX1 were lower in breast tis-
sues as compared to normal breast tissues (Fig. S3B) (http://www.
proteinatlas.org/). Therefore, we examined NLRX1 expression pattern
in different breast cancer cell lines using Western blotting. NLRX1 pro-
tein levels were low inMCF-7 and T47D (ER positive) cells as compared
toMDA-MB-231 andHBL-100 (ER negative) cells that demonstrated el-
evated levels of NLRX1 (Fig. 7A). We investigated whether NLRX1 ex-
pression in MCF-7 affected cancer phenotype using clonogenic assay
and soft agar tumorigenesis assay. The clonogenic ability of NLRX1 ex-
pressing MCF-7 cells was monitored in the presence and absence of
TNF-α. The expression of NLRX1 signiﬁcantly decreased the clonogenic
ability of MCF-7 cells in the presence of TNF-α (Fig. 7B) also shown as
plating efﬁciency (Fig. 7B′). The soft agar assay was performed to
study the role of NLRX1 in anchorage-independent cell growth. Control
MCF-7 cells were able to grow in soft agar and formed large colonies in
the presence of TNF-α. The NLRX1 expressingMCF-7 cells were not able
to grow in soft agar and formed small colonies in the presence of TNF-α,
as compared to untreated cells (Fig. 7C) plotted as colony area (Fig. C′).
We further checked whether NLRX1 expression may inhibit cell migra-
tion. MCF-7 cells were transfected with NLRX1, treated with TNF-α
treatment and the migration ability was analyzed by scratch assay.
The NLRX1 expressing MCF-7 cells displayed a signiﬁcant increase inopen wound area in the presence of TNF-α, as compared to vector
transfected cells (Fig. 7D). The low level of expression of NLRX1 in
MCF-7 may still regulate the cellular functions hence we further down-
regulated the expression by shRNA transfection. TheNLRX1 knockdown
in MCF-7 cells displayed an increased ability to form colonies
(tumorispheres) in soft agar, as compared to control cells. The size of
colonies was also increased signiﬁcantly in the presence of TNF-α
(Fig. S4A and S4B). Collectively, these results suggest that NLRX1 nega-
tively regulates tumorigenic potential andmigration ability in untreated
condition as well as in the presence of TNF-α.
3.7. NLRX1 suppresses tumorigenicity in nude mice
To extend the cellular ﬁnding to in vivo models, we used RKO
colon carcinoma cells to perform xenograft tumor formation assays
in nude mice. RKO cells expressing NLRX1 shRNA1 or ectopic full
length NLRX1 mRNA were injected into nude mice and the growths
of subcutaneous tumors were examined every two days. In agree-
ment with our in vitro studies, NLRX1 hyper expression negatively
affected the tumorigenic potential of RKO in nude mice. In contrast,
NLRX1 knockdown substantially increased the tumorigenic potential
of RKO cells in the nude mice xenograft assay (Fig. 8A). Downregula-
tion of NLRX1 signiﬁcantly increased tumor volume, as well as the
increased efﬁciency of tumor initiation. Similarly, hyper expression
of NLRX1 resulted in smaller tumor volume. The effects were
Fig. 5.NLRX1 regulated Caspase-8 activity modulates the TNF-α inducedmitochondrial ROS. (A) NLRX1 shRNA and control shRNA stable HeLa cells were treatedwith TNF-α/CHX for 4 h.
ROSproductionwasmonitoredby staining the cellswith CM-H2DCFDAﬂuorescent probe and visualizedunderﬂuorescencemicroscope. Scale bar represents 10 μm(n=2).NLRX1knock-
downwas conﬁrmed byWesternblotting using anti-NLRX1 antibody. (B) ROS levelswere analyzed in control shRNA andNLRX1 shRNA stableHEK293 cells treatedwith TNF-α/CHX in the
absence/presence of NAC (5mM) using CM-H2DCFDA (n=3). (C)Mitochondrial superoxide levelswere quantiﬁed in NLRX1 and vector transfectedMCF-7 cells treatedwith TNF-α/CHX
in the absence/presence of Mito-TEMPO (10 μM) as described in the Materials and methods section (n= 3). (D) HeLa cells were transfected with NLRX1 and control vector followed by
treatmentwith TNF-α/CHX alone or in combinationwith z-IETD-fmk for 4 h. The cellswere stainedwith CM-H2DCFDA and observed ROS production under ﬂuorescencemicroscope (n=
2). (E) Intracellular ROS levels were quantiﬁed in NLRX1 and vector transfected MCF-7 cells following treatment with TNF-α/CHX and z-IETD-fmk either alone or in combination. H2O2
treatment (50 μM) was used as a positive control (n = 3). Data in (A)–(E) depict mean ± SEM values. Asterisk (*) indicates that p value b 0.05, for SEM.
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TNF-α, after a subcutaneous inoculation of RKO cells. The TNF-α
treatment decreased the tumorigenic potential in all three RKO sub-
lines producing the smallest average tumor volume in NLRX1 ex-
pressing cancer cells (Fig. 8B, C). In vivo data from nude mice with
NLRX1 hyper expression and NLRX1 knockdown in RKO cellscorrelate with in vitro data from MCF-7 cell line both in untreated
and TNF-α treated condition. However, data with control mice in
TNF-α treated condition does not comply with the in vitro study.
This could be due to the difference in cell lines used for the in vivo
study as both the cells differ in origin and have different tumorigenic
capability [44]. Similar results were observed in other transformed
Fig. 6. NLRX1 regulates Complex I and Complex III activity to maintain ATP levels in the presence of TNF-α. (A) HEK293 cells were transfectedwith NLRX1 and vector control followed by
treatmentwith TNF-α, TNF-α/CHX, z-VAD-fmk and z-IETD-fmk either alone or in combination. (B) and (C) NLRX1 shRNA and control shRNA stable HEK293 cells were treatedwith TNF-α
and TNF-α/CHX. Complex I (B) (n = 3) and Complex III (C) (n = 2) activity were measured spectrophotometrically. (D) HEK293 cells were transfected with NLRX1 and vector control
followed by treatmentwith TNF-α, TNF-α/CHX, z-VAD-fmk and z-IETD-fmk either alone or in combination (n=3). (E)NLRX1 shRNA and control shRNA stableHEK293 cellswere treated
with TNF-α and CHX either alone or in combination. ATP levels were measured by ATP-dependent luciferase activity (n= 3). (F) Cell lysates of NLRX1 shRNA stable HeLa cells were an-
alyzed by Western blotting to check NLRX1 expression levels. Data in (A)–(E) depict mean ± SEM values. Asterisk (*) indicates that p value b 0.05, for SEM.
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absence of TNF-α (data not shown). These observations suggest that
NLRX1 may act as a potential tumor suppressor that abrogates the
tumorigenic capability of cancer cells.
4. Discussion
Chronic inﬂammation is intricately associated with promotion of
tumor initiation and progression. The high levels of pro-inﬂammatory
cytokines reprogram metabolic pathways and provide survival advan-
tage to tumor cells [45]. Increased levels of TNF-α have been consistent-
ly observed in different tumor types including breast, colorectal andgastric cancers [5]. The role of mitochondria in regulation of inﬂamma-
tory pathways is emerging. Themitochondria localized NLRX1 has been
reported to regulate both IFN and NF-κB pathways [32,33,46]. The role
of NLRX1 in controlling inﬂammation, cell death and metabolism, as
well as its participation in cancer initiation and progression is not well
understood. In the current study,we demonstrate that NLRX1 sensitizes
cells to TNF-α induced death by activating Caspase-8. The crosstalk be-
tweenNLRX1 and Caspase-8 is important for regulation ofmitochondri-
al ROS and metabolism in tumor cells.
The results obtained in the current study demonstrate that NLRX1
speciﬁcally sensitizes the cells to TNF-α induced death but does not af-
fect responses to other stress conditions. TNF-α binds to its cognate
Fig. 7.NLRX1 expression inMCF-7 cells decreases tumorigenic and cell migration property. (A) The expression of NLRX1was analyzed byWestern blotting inMCF-7, T47D, HBL-100 and
MDA-MB-231. (B and B’) MCF-7 cells were transfected with NLRX1 and control vector followed by treatment with TNF-α and clonogenic activity was assessed by counting number of
colony forming units and plotted as plating efﬁciency (n = 2). (C and C’) MCF-7 cells were transfected with NLRX1 and vector constructs and treated with TNF-α. The soft agar assay
was performed and colonies in soft agar were observed under DIC mode in ﬂuorescence microscope after 25 days. The colonies areas were measured using Image J 1.45 software
(n=2). (D)MCF-7 cells, transfectedwithNLRX1and control vectorwere subjected to TNF-α treatment and scratch assaywasperformedas indicated in theMaterials andmethods section
(n = 2). Data in (B)–(D) depict mean ± SEM. Asterisk (*) indicates that p value b 0.05, for SEM.
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many different cell types. Following the binding of TNF-α, a proximal
membrane bound complex-I is assembled by the recruitment of
TRADD adaptor protein, TRAF2, RIP1 and cIAPs. The complex-I is
known to activate NF-κB and promotes cell survival. During TNF-α in-
duced apoptosis, complex-I is internalized and recruits Caspase-8 and
FADD adaptor protein thereby forming a pro-apoptotic complex-II inthe cytoplasm [18]. The exact composition and regulation of the assem-
bly of complex-II during the TNF-α induced apoptosis is not well under-
stood. The results in the current study obtained bymeasuring cell death
and immunoprecipitation demonstrate the association of NLRX1 with
Caspase-8 and TRAF2, subunits of complex-II, in the presence of TNF-
α. The recruitment of different Ub E3 ligases [35,39,40] at this step
may ubiquitinate NLRX1 [33] and may regulate the assembly of the
Fig. 8.NLRX1 expression decreases tumorigenic potential of transformed cells in vivo. RKO
colon carcinoma cells with stable hyper expression and knockdown of NLRX1 gene were
used to study xenograft tumor formation in nude mice. (A) and (B) kinetics of tumor
growth in nude mice after injection of RKO cells with hyper expression and stable knock-
down of NLRX1 with or without treatment of TNF-α (15 μg/ml) 24 h after administration
of cancer cell line. (C) Tumor volume from untreated and TNF-α treated mice was mea-
sured every two days. Average tumor volume at day 22wasmeasured and plotted against
each RKO sublines. Data in (A)–(C) depict mean± SEM of values (n= 3). Asterisk (*) in-
dicates that p value b 0.05, for SEM.
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TNF-α induced cell death.
Caspase-8 is a multifunctional protease and translocates to differ-
ent subcellular locations during stress conditions. During ischemia
conditions, Caspase-8 translocates to the nucleus and cleaves
PARP2 [20]. Previous reports also describe the translocation of Cas-
pase-8, TRAF2 and RIP1 to mitochondria during the TNF-α induced
apoptosis. Evidences obtained in the current study suggest that
NLRX1 may regulate the association of active subunits of Caspase-8
with mitochondria in the presence of TNF-α. NLRX1 may regulatethe formation of pro-apoptotic complex-II and mediate activation
of Caspase-8 at the mitochondria to control metabolic functions in
the presence of TNF-α. This observation is in consonance with earlier
report showing that Caspase-8 may form a native macromolecular
complex with Bid at the mitochondria [47], although the functional
signiﬁcance of the association was not understood. Our results sug-
gest that NLRX1 and Caspase-8 crosstalk is important for the regula-
tion of mitochondrial ROS, as the inhibition of Caspase-8 and
knockdown of NLRX1 attenuate the TNF-α induced mitochondrial
ROS. The dysregulation of redox balance in response to TNF-α or cer-
tain pathological conditions result in leakage of electrons from Com-
plex I and Complex III to molecular oxygen, thus serving as a primary
source of superoxide anion radical. The observed mitochondria-
localized association of NLRX1 with activated Caspase-8 suggests
that the activity of Caspase-8 may inhibit the mitochondrial ETC
Complex I and Complex III. A previous report also suggests that
NDUFS1, a 75 kDa protein of mitochondrial Complex I subunit is a
substrate of Caspase-3 during apoptosis and is critical event of mito-
chondrial dysfunction during apoptosis, [41] suggesting caspase me-
diated regulation of ETC during stress conditions. Similarly, a recent
report suggests that Caspase-8 is an important bioenergetic determi-
nant and a key regulator of cellular ATP levels [48]. The results ob-
tained here also allow to hypothesize that NLRX1 may regulate the
Caspase-8 activity onmitochondria in the presence of TNF-α. The ac-
tivated Caspase-8 associated with mitochondria may cleave subunit
of mitochondrial respiratory Complex I or Complex III. The associa-
tion of NLRX1 with UQCRC2, an integral member of the Complex III
also known as the mitochondrial cytochrome bc1 complex, is consis-
tent with the hypothesis [49]. The observed TNF-α mediated de-
crease in the activity of Complex III along with the increase in
mitochondria-generated ROS in the NLRX1 expressing cells suggest
that activated Caspase-8 may target components of respiratory Com-
plex III. The additional studies are required to understand the associ-
ation of NLRX1 and Caspase-8 with mitochondrial ETC complexes
and its role in metabolism.
Cancer cells are often endowed with high intrinsic ROS generation
and constitutive NF-κB activation. Increased ROS generation coincides
with upregulated glucose metabolism under hypoxic conditions, a phe-
nomenon characteristic of fast proliferating cancer cells [50,51]. The in-
creased activities of mitochondrial Complex I and Complex III and
elevated ATP levels observed in the NLRX1 knockdown cells treated
with TNF-α suggest an increase in mitochondrial metabolic activity
and energy production. This assumption is supported by a previous re-
port showing that TNF-α regulates the expression of key metabolic
enzymes, such as glycogen phosphorylase (PYGL) and glutamate dehy-
drogenase 1 (GLUD1). PYGL increases the ﬂux of glucose from glycogen
reserveswhereas GLUD1 activity provides the substrates for anaplerotic
metabolism [52]. The current study demonstrates that NLRX1 expres-
sion inhibits the activity of mitochondrial respiratory chain, generates
ROS and sensitizes cells to TNF-α induced death. Altogether, these re-
sults implicate that NLRX1 has a tumor suppressor activity. In breast
carcinoma cells, MCF-7 and T47D, the expression of NLRX1 is compro-
mised. We show that the ectopic expression of NLRX1 in MCF-7 cells
compromised the clonogenic ability in vitro. In other human carcinoma
cell lines RKO, we observed that expression of NLRX1 also decreases
clonogenic ability in vitro and tumor formation in a nudemice xenograft
assay in vivo. Increased levels of TNF-α observed in tumor microenvi-
ronment and loss of NLRX1 expression may facilitate the metabolic
reprogramming to meet the anaplerotic demands of tumor cells. The
higher expression of NLRX1 was observed in MDA-MB-231, a highly
metastatic cell line and HBL-100, a SV40 mediated immortalized cell
line. The observations in the current study are supported by theﬁndings
of Soares et al. [38]. The authors analyzed WT versus KO cells, rather
than scramble versus knockdown cells and found a phenotype be-
tweenWT and KO cells only in transformed cells that already express
very low levels of NLRX1 inWT, rather than inWT versus KO primary
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expression of NLRX1 in KD cells changes the overall outcome of the
sensitivity to TNF-α/CHX.
This strongly suggests that NLRX1may have a different role in the
altered tumor microenvironment. Recent evidence suggests that
aggressive and metastatic properties of MDA-MB-231 cells are at-
tributed to autophagy-dependence. These cells are addicted to au-
tophagy for survival even in nutrient rich conditions [53]. Similarly,
previous reports suggest that NLRX1 acts as a positive regulator of
autophagy during antiviral signaling [54]. Altogether, these evi-
dences raise the possibility that the up-regulated expression of
NLRX1 may synergistically regulate metabolism and autophagy for
highly invasive growth of the autophagy addicted MDA-MB-231
breast cancer cells. Therefore, the tumor suppressor role of NLRX1
may be cell type dependent and will be highly speciﬁc to tumor mi-
croenvironment. The heterogeneity observed in the breast cancer
cells in tumor microenvironment further strengthens the hypothe-
sis [55]. The responsiveness of these cell lines to TNF-α induced
cell death as well as metabolic reprogramming in different cancer
types need additional studies.5. Conclusion
The results obtained in the present study suggest the role of NLRX1
in regulating the cross talk of inﬂammation, metabolism and tumori-
genesis. The proteins discovered at the interface of mitochondria and
ER, such as MAVS, MITA and NLRX1, had recently been shown to play
important roles in innate immune responses. A previous report from
our lab as well as the current study suggest that proteins regulating
NF-κB and IFN pathways may be critically linked to metabolism and
cell death [56]. The evidences presented here suggest that loss of
NLRX1 may confer dual advantage for the cells in the tumor microenvi-
ronment, as they acquire resistance to TNF-α induced cell death, while
theirmetabolic pathways are being reprogrammed tomeet the high en-
ergy and anaplerotic demands. Further studies in this direction would
help to understand the intimate connection between inﬂammation,me-
tabolism and tumor progression.Acknowledgments
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